IL-17 in Severe Asthma. Where Do We Stand?

Abstract : Asthma is a major chronic disease ranging from mild to severe refractory disease and is classified into various clinical phenotypes. Severe asthma is difficult to treat and frequently requires high doses of systemic steroids. In some cases, severe asthma even responds poorly to steroids. Several studies have suggested a central role of IL-17 (also called IL-17A) in severe asthma. Indeed, high levels of IL-17 are found in induced sputum and bronchial biopsies obtained from patients with severe asthma. The recent identification of a steroid-insensitive pathogenic Th17 pathway is therefore of major interest. In addition, IL-17A has been described in multiple aspects of asthma pathogenesis, including structural alterations of epithelial cells and smooth muscle contraction. In this perspective article, we frame the topic of IL-17A effects in severe asthma by reviewing updated information from human studies. We summarize and discuss the implications of IL-17 in the induction of neutrophilic airway inflammation, steroid insensitivity, the epithelial cell profile, and airway remodeling.
Document type :
Journal articles
Complete list of metadatas

Cited literature [93 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02163354
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Monday, June 24, 2019 - 11:39:27 AM
Last modification on : Wednesday, August 21, 2019 - 2:26:04 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Julie Chesne, Faouzi Braza, Guillaume Mahay, Sophie Brouard, Marc Aronica, et al.. IL-17 in Severe Asthma. Where Do We Stand?. American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2014, 190 (10), pp.1094-1101. ⟨10.1164/rccm.201405-0859PP⟩. ⟨inserm-02163354⟩

Share

Metrics

Record views

23